IMRX: Atebimetinib shows best-in-class survival and tolerability in first-line pancreatic cancer trials
Phase III trials of atebimetinib in first-line pancreatic cancer are progressing, with phase II data showing a median OS of 17.3 months and strong tolerability. The drug's unique mechanism and reduced toxicity differentiate it from earlier MEK inhibitors, and future strategies include synergistic c…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.